In this study, we have assessed the anti-proliferative potential of the pan-PIM kinase inhibitor AZD1208 and other PIM inhibitors in aggressive NHL-derived cell lines and compared it with PIM1 and/ or PIM2 knockdown. This evidence concerns the gene PIM2 and non-Hodgkin lymphoma.